After executing a significant IP sale, Bigfoot Biomedical looks to double down on its diabetes management platform.
Less than two years ago, Bigfoot Biomedical launched its Bigfoot Unity platform in some U.S. states. CEO Jeffrey Brewer last year called it a “transformational attempt” to simplify CGMs and the data they produce. It features a smart insulin pen cap, which takes data from a CGM and informs the patient exactly how much insulin they need.
Just last month, the company made a major play to further bolster this platform. It sold pump-based automated insulin delivery technology patents to pump maker Insulet for $25 million. This asset sale generated significant funds to expand the Bigfoot Unity diabetes management system.
Further positives followed within weeks, as Bigfoot soon after received FDA clearance for the Android mobile app for Bigfoot Unity. The mobile app allows users to input and review therapy recommendations from healthcare professionals. Users can also access a glanceable display of their current glucose range and receive real-time alerts. Bigfoot said 41% of U.S. smartphone users choose Android devices, further expanding the platform’s reach.
Brewer recently spoke to Drug Delivery Business News to discuss the asset sale and what the future looks like for Bigfoot Unity.
Get the full story at our sister site, Drug Delivery Business News.
